On April 4, 2025, Sonnet BioTherapeutics announced positive safety results for SON-1010 in a clinical trial for advanced solid tumors, allowing the study to progress to the expansion phase after a partial response was observed in one patient. The trial showed that 53% of evaluable patients had stable disease at the first follow-up, indicating potential clinical benefit.